Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29
June 30 2021 - 4:00PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, will hold its second-quarter 2021 sales and earnings
conference call with institutional investors and analysts at 8:00
a.m. EDT on Thursday, July 29. During the call, company executives
will provide an overview of Merck’s performance for the
quarter.
Investors, journalists and the general public may access a live
audio webcast of the call on Merck’s website at
https://www.merck.com/investor-relations/events-and-presentations/.
A replay of the webcast, along with the sales and earnings news
release and supplemental financial disclosures and slides
highlighting the results, will be available at www.merck.com.
Institutional investors and analysts can participate in the call
by dialing (833) 353-0277 or (469) 886-1947 and using ID code
number 5951886. Members of the media are invited to monitor the
call by dialing (833) 353-0277 or (469) 886-1947 and using ID code
number 5951886. Journalists who wish to ask questions are requested
to contact a member of Merck’s Media Relations team at the
conclusion of the call.
About Merck
For 130 years, Merck, known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases in
pursuit of our mission to save and improve lives. We demonstrate
our commitment to patients and population health by increasing
access to health care through far-reaching policies, programs and
partnerships. Today, Merck continues to be at the forefront of
research to prevent and treat diseases that threaten people and
animals – including cancer, infectious diseases such as HIV and
Ebola, and emerging animal diseases – as we aspire to be the
premier research-intensive biopharmaceutical company in the world.
For more information, visit www.merck.com and connect with us on
Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210630005848/en/
Media: Patrick Ryan (201) 452-2409 Investor: Peter Dannenbaum
(908) 740-1037 Raychel Kruper (908) 740-2107
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024